Impact of long-term buprenorphine treatment on adverse health care outcomes in medicaid

Hillary Samples, Arthur Robin Williams, Stephen Crystal, Mark Olfson

Publication Date: 05/01/2020

Abstract: The optimal, or even minimum, duration of medication treatment for opioid use disorder (OUD) needed to improve long-term outcomes has not been established empirically. As a result, health plans set potentially restrictive treatment standards to guide benefits and payment. To address this gap, we used a National Quality Forum measure for OUD medication treatment duration (180 days) to examine the impact of longer treatment on health care outcomes within a key population of Medicaid enrollees. Compared to buprenorphine discontinuation around the National Quality Forum benchmark (six to nine months), longer treatment (at least fifteen months) was associated with relative reductions in the risk of having all-cause inpatient (−52 percent) and emergency department (−26 percent) use, opioid-related hospital use (−128 percent), overdose events (−173 percent), and opioid prescriptions (−120 percent) and in the rate of prescription opioid use (−124 percent). We argue that these clinical benefits provide a rationale for policies that increase access to longer-term buprenorphine treatment, including lengthening the standards for minimum treatment duration.